Brent Adamson
AUTHOR

Brent Adamson

Tap the gear icon above to manage new release emails.
Known as having the “biggest crystal ball in B2B sales,” Brent Adamson is a world-renown researcher, author, keynote speaker, trainer, and advisor to B2B commercial executives around the world. Brent is co-author of the brand new, The Framemaking Sale, along with the best-selling, industry changing books The Challenger Sale and The Challenger Customer. He is also a frequent contributor to well-known business publications, including the Harvard Business Review, featuring his recent articles, “Sensemaking for Sales” and “Traditional B2B Sales and Marketing Are Becoming Obsolete.” A world-class facilitator and speaker, Brent has presented to tens of thousands of commercial leaders all over the world. Especially well known for his passion for “productive disruption,” Brent served as the “chief storyteller” for CEB, now Gartner’s, sales, marketing, and customer service practices from 2003 to 2022. Brent is currently Co-Founder of A to B Insight, where he continues his research and advisory work. He is also Co-Founder of Qoos, a cutting-edge, AI-guided micro-coaching platform. A native of Omaha, Nebraska, Brent received his MBA with distinction from the University of Michigan’s Ross School of Business. Prior to that, he served on the faculty of Michigan State University as a Professor of German and Applied Linguistics. In addition to his MBA, Brent holds a B.A. with distinction in political science from the University of Michigan along with M.A.s in political science and German, and a Ph.D. in applied linguistics from the University of Texas. Brent resides in Leesburg, VA with his family and rescue dog.
Read more Read less

Try Audible membership today. Start enjoying the benefits.

Try Audible for free with an audiobook of your choice.
Automatically renews at AUD $16.45/mo after 30 days. Cancel anytime.

Most Popular

Product list
  • $21.99 or free with 30-day trial

  • $26.99 or free with 30-day trial

  • $26.99 or free with 30-day trial